Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Launched by NOVARTIS · Oct 31, 2024
Trial Information
Current as of May 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Hospitalized for heart failure from 01 January 2016 to 30 September 2021.
- • Were discharged alive (any discharge disposition other than "Expired").
- • Had Mildly reduced or preserved ejection fraction (41% to 60%).
- • Had non-missing record of SAC/VAL use at discharge.
- • Continuously enrolled in Medicare Part A \& B for the 12 months following the index HF hospitalization discharge date or until death.
- Exclusion criteria:
- • Patients who left against medical advice (AMA), were transferred to an acute care facility, or discharged to hospice care.
- • Patients who had dialysis as an in-hospital procedure.
- • Patients with a medical history of chronic dialysis.
- • Patients with an in-hospital procedure of heart transplantation.
- • Patients with a medical history of heart transplantation.
- • Patients with an in-hospital procedure of left ventricular assist device.
- • Patients with a medical history of left ventricular assist device.
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
East Hanover, New Jersey, United States
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported